Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants
about
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHThe PCSK9 decadeProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesCholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemiaTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainAntagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 CellsA PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivoIdentification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein ReceptorA proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Cholesterol, the central lipid of mammalian cellsMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).A two-step binding model of PCSK9 interaction with the low density lipoprotein receptorIn silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.PCSK9: a convertase that coordinates LDL catabolism.Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP.Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblastsThe Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.Studies of the autoinhibitory segment comprising residues 31-60 of the prodomain of PCSK9: Possible implications for the mechanism underlying gain-of-function mutations.Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events.Isolation and characterization of the circulating truncated form of PCSK9Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding.Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists.How multi-scale structural biology elucidated context-dependent variability in ectodomain conformation along with the ligand capture and release cycle for LDLR family members.PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.Computational Study of PCSK9-EGFA Complex with Effective Polarizable Bond Force Field.Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice.APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.
P2860
Q24297165-D80223DA-4C39-4BFB-9EB9-D55ABF3F6D89Q24615397-B32C4610-FE14-4D7C-8EF0-6F78FCDAC381Q27009477-AC3CFCEC-B265-462C-87E3-EE94DB995644Q27013494-D318EDE3-344B-4048-8D9A-C90EF46206F5Q27339783-9C6F8971-B6E3-43BB-897F-C4A1DF7C5150Q27653836-F388DE35-48E3-4057-BD08-23473DA5A2ACQ27665195-1546B7D3-0A9C-4564-8F86-4CB5B0B1087DQ27680601-1A37264F-AD2F-4357-BD49-154419D443ECQ33532964-3B62D8E5-A031-4BAF-8F06-A5F95B5236B6Q34021021-1FD733B3-ED1A-4445-9A34-BD44DC7E74E3Q34458693-26D8F980-FC93-40E8-BDFC-7ACDC616CF0EQ34568486-5457F3B1-8DE6-4621-AD98-55F6CB0B89B6Q35740919-1BD57CB6-03AE-4D57-AED4-B4475918E3DEQ35879455-1CD4E664-A294-41AD-AB2C-9686F1F3ACB5Q36281706-40BEBF0D-7A32-4133-AC9E-E37CA3524D59Q36520347-0969A1E9-6F91-4873-BEA0-CD0DE1CD0FBDQ37173223-00DF5635-D02F-42D1-B6D8-65196CE82A13Q37657138-5A03519C-8F71-4803-8EF1-33B5D4C7211EQ37789741-A8F58DF8-9B26-4270-B8E7-AC39EAAD892CQ38001736-0108ED7B-0F80-4F75-9E85-601A764CC014Q38028561-90C624B0-2430-4F03-B797-247B80E8721CQ38151675-BA835650-CD32-424D-A254-D40FE4C2469CQ39051108-FE466055-D11F-4DCF-BAB8-1F13EF9539F9Q39080645-1F63E2A9-C98B-4BC7-A9CD-00FB3C0CFB6FQ39146866-FA610EB6-6D81-4704-9C7B-154D1ED5CA38Q39887053-E70D0937-7DEB-4954-9F63-7EC4D09435B1Q40061048-1AB45446-3716-43B2-8984-6D506AF0789AQ41198301-2CB792ED-E0CF-4B24-87EF-C1EC5BB56091Q41518234-2A77EA30-C0B7-4E12-8A4E-0E2A57550FCFQ41917702-F434E325-72F8-42CC-B238-009EC8DC8AB6Q42043417-3D65E376-5EB6-4597-A7CC-2834FB903BCEQ42660727-205A547D-83D6-41E5-A60D-F739DC0F7B90Q42908894-D747BED3-4875-4AC9-B1F1-9EC6A45BD803Q44496513-4CCF57FE-7027-4D25-AA9B-82FA2D44BBB3Q46857204-95AB0394-366E-48D4-BC32-AA020A28CDDEQ47330918-61ECDF0C-5E44-434D-9BA0-3A14B85D3B39Q47833436-E88158F0-BA35-4A3B-993C-ACCDA7A6868AQ49165041-95ED56EB-E7DB-4867-9EA5-DFBEB7629647Q50041681-FC6D65C5-EF79-4EB2-B214-ED4B8EA12002Q51007815-1EBF85E3-8870-4D44-B38F-E6A74498BDE4
P2860
Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Structural and biochemical cha ...... l hypercholesterolemia mutants
@ast
Structural and biochemical cha ...... l hypercholesterolemia mutants
@en
Structural and biochemical cha ...... l hypercholesterolemia mutants
@nl
type
label
Structural and biochemical cha ...... l hypercholesterolemia mutants
@ast
Structural and biochemical cha ...... l hypercholesterolemia mutants
@en
Structural and biochemical cha ...... l hypercholesterolemia mutants
@nl
prefLabel
Structural and biochemical cha ...... l hypercholesterolemia mutants
@ast
Structural and biochemical cha ...... l hypercholesterolemia mutants
@en
Structural and biochemical cha ...... l hypercholesterolemia mutants
@nl
P2093
P3181
P356
P1476
Structural and biochemical cha ...... l hypercholesterolemia mutants
@en
P2093
Agostino Cirillo
Alessandra Calzetta
Alessia Noto
Andrea Carfí
Ayesha Sitlani
Carl P Sparrow
Fabio Talamo
Jennifer Baysarowich
Joseph C Santoro
Laura Orsatti
P304
P3181
P356
10.1074/JBC.M808363200
P407
P577
2009-01-09T00:00:00Z